Percutaneous transluminal coronary angioplasty: Comparison of arterial vs Venous activated clotting time

被引:0
作者
Pesola, GR [1 ]
Johnson, A [1 ]
Pesola, DA [1 ]
机构
[1] MARQUETTE GEN HOSP,DEPT CARDIOL,MARQUETTE,MI
来源
CATHETERIZATION AND CARDIOVASCULAR DIAGNOSIS | 1996年 / 37卷 / 02期
关键词
ACT; PTCA; arterial vs venous; porcine;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
When arterial blood samples for activated clotting time (ACT) are difficult to obtain from the arterial sheath during coronary intervention, venous ACT serves as a substitute. Data are lacking on whether arterial and venous ACT are identical and whether one can serve as an effective substitute for the other, Forty-eight patients undergoing percutaneous transluminal coronary angioplasty (PTCA) were prospectively evaluated to answer this question. Simultaneous arterial and venous ACT samples were drawn from femoral artery and vein vascular sheaths before and during each procedure, and ACT values were determined with a Hemochron automated electronic timer. Porcine heparin dosing was guided by arterial ACT in the first 25 patients and by venous ACT in the last 23 patients. The target ACT value used for continued heparin dosing was 400 sec. At baseline and throughout the study up to 60 min, venous ACT was slightly and significantly greater than arterial ACT. Despite this statistical difference in ACT values, there was no difference in complication rate between the two groups, and the amount of heparin used during either guiding regimen was the same. Therefore, although venous ACT values are slightly higher than arterial, the more convenient venous ACT can be safely used to guide heparin dosing during PTCA when using a target ACT value of 400 sec. (C) 1996 Wiley-Liss, Inc.
引用
收藏
页码:140 / 144
页数:5
相关论文
共 23 条
  • [1] AVENDANO A, 1994, INTERVENTIONAL CARDI, V23, P907
  • [2] THE ACTS OF CORONARY ANGIOPLASTY
    BLUMENTHAL, RS
    BRINKER, JA
    [J]. CATHETERIZATION AND CARDIOVASCULAR DIAGNOSIS, 1995, 34 (01): : 6 - 7
  • [3] THE USE OF ACTIVATED CLOTTING TIMES TO MONITOR HEPARIN-THERAPY DURING AND AFTER INTERVENTIONAL PROCEDURES
    BOWERS, J
    FERGUSON, JJ
    [J]. CLINICAL CARDIOLOGY, 1994, 17 (07) : 357 - 361
  • [4] BULL BS, 1975, J THORAC CARDIOV SUR, V69, P674
  • [5] HEPARIN KINETICS - VARIABLES RELATED TO DISPOSITION AND DOSAGE
    CIPOLLE, RJ
    SEIFERT, RD
    NEILAN, BA
    ZASKE, DE
    HAUS, E
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 29 (03) : 387 - 393
  • [6] ACTIVATED CLOTTING TIMES AND ACTIVATED PARTIAL THROMBOPLASTIN TIMES IN PATIENTS UNDERGOING CORONARY ANGIOPLASTY WHO RECEIVE BOLUS DOSES OF HEPARIN
    DOUGHERTY, KG
    GAOS, CM
    BUSH, HS
    LEACHMAN, DR
    FERGUSON, JJ
    [J]. CATHETERIZATION AND CARDIOVASCULAR DIAGNOSIS, 1992, 26 (04): : 260 - 263
  • [7] COMPARISON OF ACTIVATED PARTIAL THROMBOPLASTIN TIME TO ACTIVATED CLOTTING TIME FOR ADEQUACY OF HEPARIN ANTICOAGULATION JUST BEFORE PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY
    GRILL, HP
    SPERO, JE
    GRANATO, JE
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1993, 71 (13) : 1219 - 1220
  • [8] HARRINGTON RA, 1993, CIRCULATION, V88, P1
  • [9] Hattersley P., 1966, JAMA-J AM MED ASSOC, V196, P150
  • [10] HATTERSLEY PG, 1976, AM J CLIN PATHOL, V66, P899